Document Detail

Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
MedLine Citation:
PMID:  16630136     Owner:  NLM     Status:  MEDLINE    
Malignant pleural mesothelioma (MPM) is an asbestos-related malignancy that is highly resistant to current therapeutic modalities. We established four MPM cell lines (ACC-MESO-1, ACC-MESO-4, Y-MESO-8A and Y-MESO-8D) from Japanese patients, with the latter two from the same patient with biphasic-like characteristics of MPM, showing epithelial and sarcomatous phenotypes, respectively, in cell culture. These cells grew well in RPMI-1640 medium supplemented with 10% fetal bovine serum under 5% CO2. Mutation and expression analyses demonstrated that the tumor suppressor gene NF2, which is known to be one of the most frequently mutated in MPM, is mutated in ACC-MESO-1. We detected homozygous deletion of p16INK4A/p14ARF in all four MPM cell lines. However, mutations of other tumor suppressor genes, including TP53, and protooncogenes, including KRAS, NRAS, BRAF, EGFR and HER2, were not found in these cell lines. Polymerase chain reaction amplification of the simian virus 40 sequence did not detect any products. We also analyzed genetic alterations of six other MPM cell lines and confirmed frequent mutations of NF2 and p16INK4A/p14ARF. To characterize the biological differences between Y-MESO-8A and Y-MESO-8D, we carried out cDNA microarray analysis and detected genes that were differentially expressed in these two cell lines. Thus, our new MPM cell lines seem to be useful as new models for studying various aspects of the biology of human MPM as well as materials for the development of future therapies.
Noriyasu Usami; Takayuki Fukui; Masashi Kondo; Tetsuo Taniguchi; Toshihiko Yokoyama; Shoichi Mori; Kohei Yokoi; Yoshitsugu Horio; Kaoru Shimokata; Yoshitaka Sekido; Toyoaki Hida
Related Documents :
25088936 - Variability of ki67 labeling index in multiple neuroendocrine tumors specimens over the...
9883976 - Fidelity levels of dna polymerases in tumorigenic state cells and serially transplantab...
15012776 - P16ink4a gene alterations are not a prognostic indicator for survival in patients with ...
17237836 - Pheochromocytoma: recommendations for clinical practice from the first international sy...
18714356 - Opcml is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently...
23390516 - Occludin is involved in adhesion, apoptosis, differentiation and ca(2+)-homeostasis of ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer science     Volume:  97     ISSN:  1347-9032     ISO Abbreviation:  Cancer Sci.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-04-24     Completed Date:  2006-06-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101168776     Medline TA:  Cancer Sci     Country:  England    
Other Details:
Languages:  eng     Pagination:  387-94     Citation Subset:  IM    
Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-0021, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / genetics,  metabolism,  pathology
Cell Adhesion
Cell Line, Tumor*
Cell Transformation, Neoplastic / metabolism,  pathology
Cyclin-Dependent Kinase Inhibitor p16 / genetics,  metabolism
DNA Mutational Analysis
Genes, Neurofibromatosis 2
Mesothelioma / genetics,  metabolism,  pathology*
Mice, Inbred BALB C
Mice, Nude
Middle Aged
Oligonucleotide Array Sequence Analysis
Pleural Neoplasms / genetics,  metabolism,  pathology*
Point Mutation
Tumor Suppressor Protein p14ARF / genetics,  metabolism
Reg. No./Substance:
0/Cyclin-Dependent Kinase Inhibitor p16; 0/Tumor Suppressor Protein p14ARF

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cel...
Next Document:  Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer.